文章核心观点 - 公司展示真实世界观察性注册研究数据，证明ibalizumab在降低多重耐药HIV的经大量治疗患者的HIV RNA至检测不到水平方面的有效性和安全性 [1] 研究背景 - 长期注射疗法未能消除多重耐药现象，经大量治疗的HIV患者需要能帮助建立和维持病毒学控制的抗逆转录病毒方案 [3] - PROMISE - US是一项4期、多中心、回顾性和前瞻性、观察性、非干预性注册研究，旨在评估经大量治疗的HIV患者和特定亚群的病毒学和免疫学反应的风险因素和预测因素，主要目标是评估ibalizumab与其他抗逆转录病毒疗法联合使用的长期疗效和持久性 [3] 研究数据 - 中期未匹配亚组分析包含112名参与者，队列1有70人，队列2有42人 [4] - 基线时，队列1有27人、队列2有25人病毒血症（病毒载量高于50 RNA拷贝/mL），比例分别为39%和57%（p = 0.0279） [4] - 基线时有病毒血症的参与者中，队列1有74%基线时CD4 T细胞超过200个/mm，队列2仅44%（p = 0.0376） [4] - 基线有病毒血症的患者中，治疗6个月后队列1和队列2分别有50%和47%达到病毒载量检测不到（≤50 RNA拷贝/mL）（p = 0.873） [5] - 12个月时，队列1和队列2分别有53%和42%病毒载量检测不到（p = 0.524） [5] - 队列2中ibalizumab耐受性良好，无输液反应报告，无参与者因治疗突发不良事件停药 [5] 各方观点 - 研究报告作者表示，尽管使用含ibalizumab方案的患者基线CD4计数较低、病毒载量较高，但看到病毒血症显著降低仍受鼓舞 [3] - 公司高级副总裁兼首席医学官称，PROMISE - US试验是首个在美国真实世界环境中记录多重耐药HIV经大量治疗患者长期临床结果的注册研究，数据表明ibalizumab可成为现代抗逆转录治疗方案的关键组成部分 [6] 公司信息 - 公司是一家专注于创新疗法商业化的专业生物制药公司 [7] - 公司信息可在其网站、SEDAR + 和EDGAR查询，可在领英和X上关注公司 [8]

文章核心观点 公司将于2025年3月26日美股开盘前发布2024年第四季度及全年财报，并于同日上午9点（东部时间）召开电话会议讨论结果 [1] 会议信息 - 会议时间为2025年3月26日上午9点（东部时间）/上午8点（中部时间） [3] - 可通过公司网站投资者板块观看直播 [2] - 直接电话拨号链接为https://emportal.ink/42CH3dz ，美国国内传统（接线员协助）拨号为1 - 800 - 836 - 8184，建议提前15分钟注册网络直播或拨入会议 [3] - 会议重播将在公司网站投资者板块提供 [4] 公司介绍 - 公司是北美最大的垂直整合模块化住宿及增值酒店服务提供商之一，为美国客户提供服务 [1][5] - 公司通过一系列增值解决方案，为各类终端用户建设、拥有并运营定制化且不断扩大的社区网络，包括优质餐饮服务管理、礼宾、洗衣、物流、安保和娱乐设施服务 [5] 投资者联系方式 - 联系人Mark Schuck，电话(832) 702 – 8009，邮箱[email protected] [6]

THE WOODLANDS, Texas, March 10, 2025 /PRNewswire/ -- Arrow Bidco, LLC (the "Issuer"), a Delaware limited liability company and an indirect subsidiary of Target Hospitality Corp. ("Target Hospitality", "Target", or the "Company") (NASDAQ: TH), today announced that it issued a notice of redemption (the "Redemption") to redeem all $181.4 million in aggregate principal amount outstanding of its 10.75% senior secured notes due 2025 (the "2025 Notes") on March 25, 2025 (the "Redemption Date"). This announcement d ...

文章核心观点 - 目标酒店集团与CoreCivic签订五年租赁和服务协议，重启德克萨斯州迪利市资产运营，预计带来超2.46亿美元收入，体现公司灵活运营模式优势，公司将继续寻求更多增长机会 [1][4][5] 协议基本信息 - 目标酒店集团与CoreCivic签订为期五年的租赁和服务协议，重启位于德克萨斯州迪利市的资产运营 [1] - 该资产曾在2014年9月至2024年8月期间作为南德克萨斯家庭住宅中心运营，重启后设施规模和运营范围与之前相似 [2] 设施情况 - 迪利设施可容纳多达2400人，能提供开放安全环境，社区布局无需资本投资，可无缝重启 [3] 财务预期 - 迪利合同预计在五年内带来超2.46亿美元收入，到2030年3月结束，预计2025年实现约3000万美元收入 [4] 公司优势与展望 - 社区的无缝重启体现目标酒店集团灵活运营模式和独特能力，支持公司响应客户需求，提供定制化解决方案 [5] - 公司认为这些核心竞争力为评估支持美国政府移民政策的增长机会及其他多元化增长计划奠定基础 [5] 公司表态 - 公司总裁兼首席执行官表示很高兴继续与CoreCivic合作，重启社区体现资产战略重要性和公司提供关键服务及酒店解决方案的能力，公司将继续寻求支持美国政府的潜在机会 [6] 协议支持与条件 - 迪利合同得到德克萨斯州迪利市与美国移民和海关执法局修订的政府间服务协议支持，该协议和迪利合同需经美国政府年度拨款，可提前60天通知取消 [7] 公司简介 - 目标酒店集团是北美最大的垂直整合模块化住宿和增值酒店服务提供商之一，为终端用户提供定制化社区网络及一系列增值解决方案 [8]

The market expects Target Hospitality (TH) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if ...

Target Hospitality (TH) has been beaten down lately with too much selling pressure. While the stock has lost 41.5% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator t ...

Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million Achieved record quarterly revenue of $25 million and annual revenue of $85.9 million New credit facilities’ favorable interest rates and amortization schedules free up approximately $19 million in cash in 2025 In-licensed two new Ionis assets in Canada to drive long-term growth MONTREAL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or t ...

THE WOODLANDS, Texas, Feb. 24, 2025 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality", "Target" or the "Company") (Nasdaq: TH), one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, received notice that the U.S. government intends to terminate the existing Pecos Children's Center ("PCC") services agreement with Target's nonprofit partner ("NP Partner"), effective immediately, or on or about February 21, 2025 ("Effective Da ...

MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2024 ended November 30 on Wednesday, February 26, 2025, at 8:30 a.m. ET. The call will be hosted b ...

MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced that it has resumed distribution of EGRIFTA SV® (tesamorelin for injection), following correspondence from the U.S. Food and Drug Administration (FDA) that allows the Company to release two recently manufactured ba ...